Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.33 |
| ▸ | LDHB | P07195 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126580 | 0.73 | NPSR1 (0.51) | ALDH1A1MEN1POLBKMT2ALMNA | |
| SCHEMBL4552206 | 0.72 | GABRA1 (0.31) | — | |
| SCHEMBL4495791 | 0.65 | LDHA (0.37) | LDHALDHBALB | |
| SCHEMBL3156800 | 0.64 | CYP1A2 (0.54) | ALDH1A1CYP1A2CYP3A4MEN1POLB | |
| SCHEMBL24716896 | 0.64 | BCAT2 (0.36) | ALDH1A1MEN1POLBKMT2ALMNA | |
| SCHEMBL9335819 | 0.63 | MEN1 (0.69) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL30410098 | 0.63 | HAAO (0.39) | LDHALDHBALDH1A1CYP1A2MEN1 | |
| SCHEMBL13245759 | 0.61 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP3A4MEN1POLB | |
| SCHEMBL3118025 | 0.61 | JAK2 (0.48) | ALDH1A1EIF4A3CYP1A2CYP3A4LMNA | |
| SCHEMBL5513393 | 0.61 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| EP-2076492-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008054605-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | LDHA 3198/4885LDHB 2798/4885ALDH1A1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.